Navigation Path Index
This generated index groups all source notes by their nav_path. It is the bridge between the Word navigation evidence and the topic wiki.
| nav path | count | source notes |
|---|---|---|
| 4 LPS | 1 | 20240722_184639 |
| 7T MRI | 1 | 20240722_184153 |
| AGS (Aicardi-Goutieres Syndrome) / cGAS transition > Parkin > PARK2 Gene (=PRKN) | 1 | 20240722_181851 |
| Assay Development LC-MS | 1 | 20240722_184703 |
| Assays of pyroptosis | 1 | 20240722_183203 |
| Assays of pyroptosis (cytokine / chemokine omics) > AD | 1 | 20240722_183215 |
| Assays of pyroptosis > Budget & FTE > Ceri > Chemistry | 1 | 20240722_183208 |
| Assessment of mitochond… > Summary > 31P MRS imaging > Principle | 1 | 20240722_183505 |
| BIOMARKER > Validity > Milestones > Milestone: MBM Only | 1 | 20240722_184723 |
| Background > Pipeline C5aR1 > Innomedica (Haven) > In Vivo Clibration | 1 | 20240722_183342 |
| Brain Bank | 1 | 20240722_184200 |
| Brain Bank > Clinical Progression > Clinical Trial example > Cohort | 1 | 20240722_184203 |
| Comp Bio | 1 | 20240722_183212 |
| Cryopyrin-Associated Periodic Syndromes (CAPS) | 1 | 20240722_183138 |
| DD > Progress | 1 | 20240722_183339 |
| DNL151 (=BIIB12…) > Clinical trials > Preclinical | 1 | 20240722_183410 |
| Diagnosis of PD | 1 | 20240722_183111 |
| Dose of PET tracer > PET Steering Committee > Workflow > Preclinical study | 1 | 20240722_184826 |
| Example of Pathway Analy… | 1 | 20240722_184509 |
| FY21 > FY21 MRP | 1 | 20240722_184847 |
| FY21 B. KPI-linked projects > FY21 MRP > Glossary > Amino Acid Codes | 1 | 20240722_184901 |
| FY21 B. KPI-linked proje… > FY21 MRP > Glossary > Amino Acid Codes | 1 | 20240722_184857 |
| Function > Steps of cellular respiration | 1 | 20240722_183439 |
| GAPFREE3 (iPSC, Yuya Kunisada) > Mid-brain organoids with FTD-tau (University of Cambridge) > Iron > Normal roles of iron > Normal distribution of iron > Normal physiology > Ferritin | 1 | 20240722_183345 |
| GAPFREE3 > Preclinical support | 1 | 20240722_184138 |
| GAPFREE3 > Preclinical support > ARG | 1 | 20240722_184142 |
| GT > Cell therapy > Inflammation > 기타 MOA들 | 1 | 20240722_184344 |
| General recommendations > Detailed recommendations > Protein level > General | 1 | 20240722_184620 |
| Genes Mitochondria > PRS Mitochondria > MC1 PET > MC1 PET studies | 1 | 20240722_183524 |
| Genetic Association Study | 1 | 20240722_184633 |
| Havrda | 1 | 20240722_183228 |
| Imaging neuroinflammation | 1 | 20240722_183104 |
| Imaging neuroinflammation > DPA714 > 3rd Generation TSPO | 1 | 20240722_183108 |
| In Vivo strategy > Katy | 1 | 20240722_183234 |
| In Vivo strategy > Katy > Longitudinal | 1 | 20240722_183241 |
| Inflammation > Competitor > Havrda | 1 | 20240722_183225 |
| Inflammation > In Vivo strategy > Katy | 1 | 20240722_183238 |
| Inflammation > NLRP3 > Neuronal > Caspase 1 > aSyn splicing > Catalytic cleft | 1 | 20240722_183135 |
| Inflammation > NLRP3 > Tx | 1 | 20240722_183147 |
| Inflammation > NLRP3 inhibitor (Marianthi) > AD > Assays of pyroptosis | 1 | 20240722_183159 |
| Inflammation > 기타 MOA들 > Pittsburgh University > Greenamyre Lab | 1 | 20240722_184357 |
| Insertions > Deletion/insertions (indels) > Extensions | 1 | 20240722_184623 |
| LRRK2 Clinical trials > Other LRRK2 pipeline > Prevalence > Protein > Lysosome > Structure of Lysosome > Ion channels and Transporters | 1 | 20240722_183413 |
| Life-cycle > Localization > Manufacturing > PK/PD strategy | 1 | 20240722_184749 |
| Liquid Nitrogen > Longitudinal | 1 | 20240722_183358 |
| Longitudinal > 4 LRRK2 > Animal models of LRRK2 > Inflammation and LRRK2 | 1 | 20240722_183401 |
| Lysosomal Enzymes | 1 | 20240722_183416 |
| MOA of Mitophagy | 1 | 20240722_184146 |
| MOA of NPC > NFL > Age > PD | 1 | 20240722_184250 |
| MSA | 1 | 20240722_184206 |
| MSA > Dx of MSA > Imaging | 1 | 20240722_184210 |
| MSA > Outcome Measures > Pathology | 1 | 20240722_184219 |
| MSA > Outcome Measures > Unified MSA Rating Scale (UMSARS) | 1 | 20240722_184216 |
| MSA > Pathology > TM in MSA > Mucolipidosis (ML) | 1 | 20240722_184233 |
| MSA > Pipeline MSA > Disease-modifying | 2 | 20240722_184223, 20240722_184226 |
| MSA > aSyn in MSA > CSF aSyn in MSA | 1 | 20240722_184156 |
| Macroautophagy > Microautophagy > CMA > BMP (Bis(monoacylglycero…)) | 1 | 20240722_183423 |
| Magnetoencephalography (MEG) > Maiko Tanaka > Metabolomics > MIBG | 1 | 20240722_183426 |
| Maiko Tanaka > Metabolomics > MIBG > Milestones (process) | 1 | 20240722_183432 |
| Measurement of OS > Route of Administration > ICM (= Suboccipital puncture) > Peripheral leak/transduction | 1 | 20240722_184443 |
| Microglial Imaging | 1 | 20240722_183247 |
| Microglial Imaging > Modelling > NHP > PDE | 1 | 20240722_183250 |
| Milestones (process) | 1 | 20240722_183429 |
| Minee Choi > Kv1.3 > Kyoko Yoshikawa > Lee Jonghun | 1 | 20240722_183354 |
| Mitochondrial DNA > Mitochondrial genes > Methylation of mt DNA > Mitochondrial turnover > Mitochondrial transcription (biogenesis) > Mitochondrial DYNAMICS (fusion/fission and transportation) > Mitochondrial Regulators > Circulating cell-free mitochondria in blood | 1 | 20240722_183452 |
| Mitochondrial DNA home… > Location of mitochondria > Structure of mitochondria > Rotenone | 1 | 20240722_183446 |
| Mitochondrial Regulators > Circulating cell-free mitochondrial DNA > Assessment of mitochondrial function > Summary | 1 | 20240722_183501 |
| Mitochondrial Regulators > Circulating cell-free mitoch… > Assessment of mitochond… > Summary | 1 | 20240722_183458 |
| MoCA (Montreal Cognitive Assessment) | 1 | 20240722_184306 |
| MoCA (Montreal Cognitive… | 1 | 20240722_184456 |
| Mutation | 1 | 20240722_183404 |
| NDU > DDU Subteam > 20201022 Kick off > Sharefolder | 1 | 20240722_184237 |
| NFL | 1 | 20240722_184213 |
| NFL > PD | 1 | 20240722_184253 |
| NHP > Marmoset > Cynomolgus (Macaca fascicularis) > On-Off Phenomenon | 1 | 20240722_184256 |
| NHP > PDE > PE > PET | 1 | 20240722_183301 |
| NLRP3 > Structure | 1 | 20240722_183132 |
| NLRP3 > Toxicity | 1 | 20240722_183144 |
| NLRP3 inhibitor (Marianthi) (P…) > AD > Assays of pyroptosis | 1 | 20240722_183156 |
| NLRP3 inhibitor (Marianthi) (P…) > Pipeline / Competitors | 1 | 20240722_183222 |
| Neurogenomics Partnership | 1 | 20240722_184244 |
| Niemann-Pick disease | 1 | 20240722_184247 |
| Outcome measures > Original UPDRS (1987) | 1 | 20240722_184300 |
| Outcome measures > Original UPDRS (1987) > MDS-UPDRS’ = Modified… > (Simuni, 2018 #198) | 1 | 20240722_184303 |
| Outcome measures > Sandy > Screenig > Scientst.com > Schizophrenia | 1 | 20240722_184450 |
| P2P | 1 | 20240722_184525 |
| P2P > TMQB > Toxins > Paraquat > MPTP | 1 | 20240722_184522 |
| P2P Platform Trial | 1 | 20240722_184529 |
| P2P Platform Trial > Progranulin (PGRN) > Denali Progranulin PTV > PD and PGRN | 1 | 20240722_184410 |
| PADD > Pathogenicity of variant > Pathway Analysis > Example of Pathway Analysis | 1 | 20240722_184317 |
| PARKN GT (Takeshi Hioki, PFR-4249-100) > NHP Studies > Bioanalytical method to differentiate human and monkey Parkin | 2 | 20240722_182043, 20240722_182046 |
| PARKN GT (Takeshi Hioki, PFR-4249-100) > Natural Hx study > Quantitative BM criteria / Target validation | 1 | 20240722_182050 |
| PARKN GT (Takeshi Hioki, PFR-4249-100) > PE > PET | 3 | 20240722_182053, 20240722_182057, 20240722_182100 |
| PARKN GT (Takeshi Hioki, PFR-4249-100) > RD DDU’s PET Imaging GBA > PK/PD Strategy | 1 | 20240722_182103 |
| PARKN GT (Takeshi Hioki, PFR-4249-100) > Safety > Sharefolder | 1 | 20240722_182106 |
| PARKN GT (Takeshi Hioki, PFR-4249-100) > TM > Assays | 1 | 20240722_182110 |
| PD Proteomics | 1 | 20240722_184417 |
| PD and PGRN > MJF > Prophylactic vs Therapeutic > Protein tags | 1 | 20240722_184413 |
| PDE > PIAS2 > Pipeline of PD > aSyn - Antibody | 1 | 20240722_184324 |
| PE > PET > Chemistry PET | 1 | 20240722_183252 |
| PET | 1 | 20240722_183258 |
| PET > RBD (REM sleep behavior disorder) > Symptom > Incidence | 1 | 20240722_184427 |
| PET Steering Committee > Workflow > Preclinical study > Clinical study | 1 | 20240722_184829 |
| PINK-1 | 1 | 20240722_182116 |
| PK-PD relationship > [PET] > Antibody radiolabelling > Parameters of PET ligand | 1 | 20240722_184813 |
| PK/PD > PK/PD Strategy | 1 | 20240722_183305 |
| PK/PD strategy > Dose Scaling for GT > Promoter | 1 | 20240722_184753 |
| PRS Mitochondria > MC1 PET > MC1 PET studies > Preclinical support | 1 | 20240722_184135 |
| Parameters of PET ligand > Dose of PET tracer > PET Steering Committee > Workflow | 1 | 20240722_184816 |
| Parkin > PARKN GT (Takeshi Hioki, PFR-…) > Executive summary | 1 | 20240722_182014 |
| Parkin > PARKN GT (Takeshi Hioki, PFR-4249-100) | 4 | 20240722_182011, 20240722_182021, 20240722_182025, 20240722_182029 |
| Parkin > PARKN GT (Takeshi Hioki, PFR-4249-100) > Clinical strategy | 1 | 20240722_182018 |
| Parkin > PARKN GT (Takeshi Hioki, PFR-4249-100) > NHP Studies > Current plan | 1 | 20240722_182040 |
| Parkin > PARKN GT (Takeshi Hioki, PFR-4249-100) > Natural Hx study > Sample size estimation | 1 | 20240722_182033 |
| Parkin > PARKN GT (Takeshi Hioki, PFR-4249-100) > Natural Hx study > Sample size estimation > NHP Studies > Current plan | 1 | 20240722_182036 |
| Parkin > Parkin PD | 13 | 20240722_181910, 20240722_181921, 20240722_181925, 20240722_181932, 20240722_181936, 20240722_181939, 20240722_181943, 20240722_181947, 20240722_181950, 20240722_181954, 20240722_182001, 20240722_182004, 20240722_182007 |
| Parkin > Parkin PD > Clinical strategy > Natural Hx study | 1 | 20240722_181907 |
| Parkin > Parkin PD > pS65-Ub | 1 | 20240722_181958 |
| Parkin > Parkin protein > KO Parkin | 1 | 20240722_181855 |
| Parkin > Parkin protein > Location / States / Structure / Substrates transition | 1 | 20240722_181859 |
| Parkin > Parkin protein > Substrates (& function) of Parkin > Parkin PD | 1 | 20240722_181903 |
| Parkin, > Parkin PD | 3 | 20240722_181914, 20240722_181917, 20240722_181928 |
| Parkin, > TM > Assays > IVC > Parkin activity assay? > TMQB > TPP/TCP > Unmet Needs > Vector production > PINK-1 | 1 | 20240722_182113 |
| Pathogenicity of variant | 1 | 20240722_184314 |
| Pathway Analysis > Example of Pathway Analysis > PDE | 1 | 20240722_184320 |
| Pipeline > Radiochemical > Rare Disease > PET | 1 | 20240722_184424 |
| Pipeline CAPS | 1 | 20240722_183150 |
| Pipeline MSA > Disease-modifying > RBD screening question… > RBDQ-HQ (REM sleep…) > Mechanism > Pathology/Imaging | 1 | 20240722_184430 |
| Pipeline MSA > Subtype | 1 | 20240722_184230 |
| Pipeline of GD & GBA-PD | 1 | 20240722_181741 |
| Pipeline of GD & GBA-PD > GBA > Catalytic pathway | 1 | 20240722_182203 |
| Pipeline of GD & GBA-PD > GBA > Catalytic pathway > Gangliosides | 2 | 20240722_182207, 20240722_182210 |
| Pipeline of GD & GBA-PD > GBA > Catalytic pathway > Gangliosides > GlcSph | 1 | 20240722_182213 |
| Pipeline of GD & GBA-PD > GBA > GBA activity (BGL test) | 1 | 20240722_182200 |
| Pipeline of GD & GBA-PD > GBA > Structure of GBA protein | 1 | 20240722_182157 |
| Pipeline of GD & GBA-PD > GBA-PD > Animal models of GBA-PD | 1 | 20240722_182306 |
| Pipeline of GD & GBA-PD > GBA-PD > Correction studies | 2 | 20240722_182310, 20240722_182313 |
| Pipeline of GD & GBA-PD > GBA-PD > GBA Activator > Acid ceramidase inhibitor | 1 | 20240722_182406 |
| Pipeline of GD & GBA-PD > GBA-PD > GBA Activator > Competitor | 1 | 20240722_182355 |
| Pipeline of GD & GBA-PD > GBA-PD > GBA Activator > Competitor > Fusion Protein | 1 | 20240722_182358 |
| Pipeline of GD & GBA-PD > GBA-PD > GBA Activator > GALC (galactosylceramidase) > Genetics GALC for PD | 1 | 20240722_182409 |
| Pipeline of GD & GBA-PD > GBA-PD > GBA Activator > GalactosylSph (=psychosine) > Assay of GalactosylSph | 1 | 20240722_182412 |
| Pipeline of GD & GBA-PD > GBA-PD > GBA Activator > NHP Translational Model | 1 | 20240722_182351 |
| Pipeline of GD & GBA-PD > GBA-PD > GBA Activator > Pipeline of KD > Target validation and correction | 1 | 20240722_182416 |
| Pipeline of GD & GBA-PD > GBA-PD > GBA Activator > RD DDU’s PET Imaging GBA | 1 | 20240722_182402 |
| Pipeline of GD & GBA-PD > GBA-PD > GBA Activator > RD-DDU GBA Activator | 1 | 20240722_182336 |
| Pipeline of GD & GBA-PD > GBA-PD > GBA Activator > Target validation and correction > 총정리중 GBA+PD에서 Lys | 1 | 20240722_182419 |
| Pipeline of GD & GBA-PD > GBA-PD > GBA GT > Executive summary | 1 | 20240722_182339 |
| Pipeline of GD & GBA-PD > GBA-PD > GBA GT > NHP studies > SNBR (Shin Nippon Biomedical Laboratories) | 1 | 20240722_182343 |
| Pipeline of GD & GBA-PD > GBA-PD > GBA GT > TM GT GBA-PD | 1 | 20240722_182346 |
| Pipeline of GD & GBA-PD > GBA-PD > GBA vs UPDRS vs MOCA | 3 | 20240722_182316, 20240722_182320, 20240722_182323 |
| Pipeline of GD & GBA-PD > GBA-PD > MOA GBA-PD | 1 | 20240722_182259 |
| Pipeline of GD & GBA-PD > GBA-PD > Motor vs Cognition | 1 | 20240722_182303 |
| Pipeline of GD & GBA-PD > GBA-PD > Mutation GBA-PD | 1 | 20240722_182255 |
| Pipeline of GD & GBA-PD > GBA-PD > PET Imaging GBA | 2 | 20240722_182326, 20240722_182330 |
| Pipeline of GD & GBA-PD > GBA-PD > PET Imaging GBA > GBA Activator | 1 | 20240722_182333 |
| Pipeline of GD & GBA-PD > GD > Animal models of GD | 2 | 20240722_182233, 20240722_182237 |
| Pipeline of GD & GBA-PD > GD > Animal models of GD > Outcome measure in nGD | 1 | 20240722_182241 |
| Pipeline of GD & GBA-PD > GD > Mutations Summary | 1 | 20240722_182216 |
| Pipeline of GD & GBA-PD > GD > Parameters > GD 1 Summary | 1 | 20240722_182224 |
| Pipeline of GD & GBA-PD > GD > Parameters > GD 3 Summary | 2 | 20240722_182227, 20240722_182230 |
| Pipeline of GD & GBA-PD > GD > Parameters > Oculomotor measurements | 2 | 20240722_182245, 20240722_182252 |
| Pipeline of GD & GBA-PD > GD > Parameters > Retina in nGD | 1 | 20240722_182248 |
| Pipeline of GD & GBA-PD > GD > Types and Neuropathology | 1 | 20240722_182219 |
| Pipeline of GD & GBA-PD > Prevail PR001 | 3 | 20240722_181800, 20240722_181805, 20240722_181809 |
| Pipeline of GD & GBA-PD > Summary | 4 | 20240722_181748, 20240722_181752, 20240722_181813, 20240722_182123 |
| Pipeline of GD & GBA-PD > Summary > GBA | 1 | 20240722_182153 |
| Pipeline of GD & GBA-PD > Summary > 총정리 GBA protein & activity | 4 | 20240722_182126, 20240722_182130, 20240722_182133, 20240722_182146 |
| Pipeline of GD & GBA-PD > Summary > 총정리 GBA protein & activity > Read the Paper | 1 | 20240722_182143 |
| Pipeline of GD & GBA-PD > Summary > 총정리 GBA protein & activity > Summary GBA protein & activity | 1 | 20240722_182139 |
| Pipeline of GD & GBA-PD > Summary > 총정리 GBA protein & activity > Summary GBA protein & activity, GlcCer, GlcSph | 1 | 20240722_182136 |
| Pipeline of GD & GBA-PD > Summary > 총정리 GBA protein & activity > a-syn POSTMORTEM | 1 | 20240722_182149 |
| Pipeline of GD & GBA-PD > Supplement > ATP13A2 (Park9) > BBB / disruption / opener > BD > Process / BeyondBio > Biobank | 1 | 20240722_182613 |
| Pipeline of GD & GBA-PD > Supplement > Antibody > Epitope mapping > APOE > AQP4 potentiator | 1 | 20240722_182447 |
| Pipeline of GD & GBA-PD > Supplement > Assay Truncation > Structure of aSyn > Synapse and aSyn > TM for aSyn programs | 1 | 20240722_182606 |
| Pipeline of GD & GBA-PD > Supplement > Astrocytic aSyn > CSF & Blood (a-syn) > Distribution > Expression of aSyn | 1 | 20240722_182514 |
| Pipeline of GD & GBA-PD > Supplement > Basal Ganglia > MBN (nucleus basalis of M…) > Development of brain (bra…) > Brainstem | 1 | 20240722_182436 |
| Pipeline of GD & GBA-PD > Supplement > BeyondBio > Biobank > MJF > Netherlands Brain Bank | 2 | 20240722_182620, 20240722_182624 |
| Pipeline of GD & GBA-PD > Supplement > Biobank > MJF > Netherlands Brain Bank > Imperial College Brain Bank | 1 | 20240722_182627 |
| Pipeline of GD & GBA-PD > Supplement > CNS & PNS > Cerebral Cortex | 1 | 20240722_182422 |
| Pipeline of GD & GBA-PD > Supplement > Cerebral Cortex > Neuron > Synapse | 1 | 20240722_182426 |
| Pipeline of GD & GBA-PD > Supplement > Cranial nerve > Facial n > Nigrostriatal pathway > Basal Ganglia | 1 | 20240722_182433 |
| Pipeline of GD & GBA-PD > Supplement > Function (of normal aSyn) > Grading/Scoring of LB pathology > Homology > In vitro studies of aSyn | 1 | 20240722_182518 |
| Pipeline of GD & GBA-PD > Supplement > Gut > Commissures > Anatomy-Neurological signs > General | 1 | 20240722_182440 |
| Pipeline of GD & GBA-PD > Supplement > Imperial College Brain Bank > Other Biobanks > Biobanks in Japan > BIOMARKER | 3 | 20240722_182641, 20240722_182644, 20240722_182704 |
| Pipeline of GD & GBA-PD > Supplement > MJF > Netherlands Brain Bank > Imperial College Brain Bank > Other Biobanks | 2 | 20240722_182630, 20240722_182634 |
| Pipeline of GD & GBA-PD > Supplement > MOA of aSyn spreading > Antibodies to aSyn > Astrocytic aSyn > CSF & Blood (a-syn) | 1 | 20240722_182510 |
| Pipeline of GD & GBA-PD > Supplement > Mutations SNCA > Neurodegeneration and aS… > Oligodendrocytic aSyn > PET aSyn | 1 | 20240722_182522 |
| Pipeline of GD & GBA-PD > Supplement > Mutations SNCA > Neurodegeneration and aSyn > Oligodendrocytic aSyn > PET aSyn | 4 | 20240722_182524, 20240722_182528, 20240722_182532, 20240722_182535 |
| Pipeline of GD & GBA-PD > Supplement > NDE > Fragments (Truncation) > Assay Truncation > Structure of aSyn | 1 | 20240722_182602 |
| Pipeline of GD & GBA-PD > Supplement > Netherlands Brain Bank > Imperial College Brain Bank > Other Biobanks > Biobanks in Japan | 1 | 20240722_182637 |
| Pipeline of GD & GBA-PD > Supplement > Neurodegeneration and aSyn > Oligodendrocytic aSyn > PET aSyn > Postmortem aSyn | 1 | 20240722_182539 |
| Pipeline of GD & GBA-PD > Supplement > Neuron > Synapse > Postsynaptic density > Cranial nerve | 1 | 20240722_182429 |
| Pipeline of GD & GBA-PD > Supplement > Non-Spreading Models > Spreading Models > Summary of a-syn animal models > MOA of aSyn spreading | 1 | 20240722_182504 |
| Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra | 1 | 20240722_182708 |
| Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Blood | 2 | 20240722_182711, 20240722_182715 |
| Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Blood > PBMC > Vendors of PBMC | 1 | 20240722_182718 |
| Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Braak Staging | 2 | 20240722_182722, 20240722_182725 |
| Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > CEI > Cerevance > Deliverables | 1 | 20240722_182752 |
| Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > CEI > Cerevance > Team | 1 | 20240722_182755 |
| Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > CEI > Companies CEI | 4 | 20240722_182728, 20240722_182732, 20240722_182735, 20240722_182738 |
| Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > CEI > Summary CEI | 3 | 20240722_182742, 20240722_182745, 20240722_182749 |
| Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Cholinergic > CSF | 1 | 20240722_182833 |
| Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Cholinergic > CSF Flow | 1 | 20240722_182836 |
| Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Cholinergic > Consortium | 2 | 20240722_182824, 20240722_182827 |
| Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Cholinergic > Contacts | 1 | 20240722_182830 |
| Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Cholinergic > DLB vs PDD vs MSA | 2 | 20240722_182904, 20240722_182907 |
| Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Cholinergic > DNA damage | 1 | 20240722_182910 |
| Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Cholinergic > Diagnosis of PD | 1 | 20240722_182848 |
| Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Cholinergic > Digital Trials | 3 | 20240722_182851, 20240722_182854, 20240722_182857 |
| Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Cholinergic > Disease area TM strategy | 1 | 20240722_182900 |
| Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Cholinergic > Human CSF sampling | 1 | 20240722_182839 |
| Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Cholinergic > Interferons > interferon-stimulated gene | 1 | 20240722_182842 |
| Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Cholinergic > Multiplex cytokine assay | 1 | 20240722_182845 |
| Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Cholinergic > Pathology | 1 | 20240722_182821 |
| Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Cholinergic > Prevalence | 1 | 20240722_182815 |
| Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Cholinergic > vMRI | 1 | 20240722_182818 |
| Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Circuits > Direct pathway | 1 | 20240722_182758 |
| Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Circuits > Indirect pathway | 1 | 20240722_182802 |
| Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Comorbidity > Signals > Inflammasome > In vitro model of neuroinflammation | 1 | 20240722_183055 |
| Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Dopamine system > Dopa Imaging | 1 | 20240722_182919 |
| Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Dopamine system > Dopamine metabolites in PD | 1 | 20240722_182913 |
| Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Dopamine system > Neuromelanin pigment | 1 | 20240722_182932 |
| Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Dopamine system > Neuromelanin-MRI | 2 | 20240722_182935, 20240722_182938 |
| Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Dopamine system > Summary of dopamine system | 1 | 20240722_182916 |
| Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Dopamine transporter Imaging > DATscan in PD | 2 | 20240722_182922, 20240722_182926 |
| Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Dopamine transporter Imaging > Rodent Dopamine transporter | 1 | 20240722_182929 |
| Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Dose finding > Delayed start design | 1 | 20240722_182811 |
| Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Dose finding > Dose selection/finding | 1 | 20240722_182805 |
| Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Dose finding > Sample size calculation | 1 | 20240722_182808 |
| Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Druggability | 1 | 20240722_182941 |
| Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Druggability > DWI vs DTI | 1 | 20240722_182944 |
| Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Druggability > DWI vs DTI > Dyskinesia > Clinical presentation of Dyskinesia in PD > MOA of Dyskinesia | 1 | 20240722_182947 |
| Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Druggability > DWI vs DTI > Dyskinesia > Clinical presentation of Dyskinesia in PD > MOA of Dyskinesia > Outcome Measures Dyskinesia > Animal models of Dyskinesia > Pipeline of Dyskinesia | 1 | 20240722_182950 |
| Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Druggability > DWI vs DTI > Dyskinesia > Pipeline of Dyskinesia > EEG > Bands > EEG in PD | 1 | 20240722_182953 |
| Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > EEG > Bands > EEG in PD > Limitations > Sleep EEG > Effect size | 1 | 20240722_182956 |
| Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > EEG > EEG in PD > Limitations > Sleep EEG > Effect size | 1 | 20240722_182959 |
| Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > EEG > Effect size > Efficacy modelling > Electrophysiology > Anatomy of a neuron > Methods | 1 | 20240722_183002 |
| Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Electrophysiology > Anatomy of a neuron > Methods > Resting potential (Inactive state) > Process | 1 | 20240722_183006 |
| Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Electrophysiology > Process > voltage-dependent ion channels > ERB > Endoplasmic Reticulum (ER) > 4 Exosome | 1 | 20240722_183009 |
| Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Endoplasmic Reticulum (ER) > 4 Exosome > ConsoRCC > Example > 4 NDE > neuronal exosome enrichment procedure > Oligodendrocyte-derived exosome | 1 | 20240722_183012 |
| Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > GABA imaging > Gait > 4 Gait > Assessment of Gait > Galectin-3 > GCS inhibitor | 1 | 20240722_183018 |
| Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > GPR37 > Glossary > H&Y (Hoehn and Yahr) | 1 | 20240722_183034 |
| Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > GWAS > Modifiers > Summary > LSD genes | 1 | 20240722_183028 |
| Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > GWAS > Summary > LSD genes > GPR37 > Glossary > H&Y (Hoehn and Yahr) | 1 | 20240722_183031 |
| Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Gladstone Institute > Glutamate > Imaging > Goals > FY22 | 1 | 20240722_183021 |
| Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Goals > FY22 > GWAS > Modifiers > Summary | 1 | 20240722_183024 |
| Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > H&Y (Hoehn and Yahr) > HA-tag > Hearing loss | 1 | 20240722_183037 |
| Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > HR Performance Review (including 360) > Human Biological Samples > Imaging > PET | 1 | 20240722_183044 |
| Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Hearing loss > Heuron > Hirozane, Yoshihiko > HR Performance Review (including 360) | 1 | 20240722_183040 |
| Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Immunity > Autoimmunity (Autoantibody) > Evidence > ImmunoPET > Imnewrun | 1 | 20240722_183047 |
| Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Inflammasome > In vitro model of neuroinflammation > Imaging neuroinflammation | 2 | 20240722_183058, 20240722_183101 |
| Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Inflammasome > In vitro model of neuroinflammation > Imaging neuroinflammation > Structure of microglia > Phenotypes of microglia > Markers of microglia | 1 | 20240722_183115 |
| Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Inflammation > ALS > aSyn (therapeutic) antibody > Comorbidity | 1 | 20240722_183050 |
| Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Oligodendrocyte-derived exosome > Eye > Fibroblast > Cell model system for CNS? > GABA > Further readings > GABA imaging > review (Magrinelli, 2016 #1063) | 1 | 20240722_183015 |
| Pipeline of GD & GBA-PD > Supplement > PD > Animal model > CROs > Database > Antibody > Epitope mapping | 1 | 20240722_182443 |
| Pipeline of GD & GBA-PD > Supplement > PET for astrocyte > aSyn > Animal models of aSyn > Non-Spreading Models | 1 | 20240722_182451 |
| Pipeline of GD & GBA-PD > Supplement > Postmortem aSyn > Release > Safety for aSyn > KO of α-syn > Seed-Amplification Assay | 1 | 20240722_182542 |
| Pipeline of GD & GBA-PD > Supplement > Process > BeyondBio > Biobank > MJF | 1 | 20240722_182617 |
| Pipeline of GD & GBA-PD > Supplement > Safety for aSyn > KO of α-syn > Seed-Amplification Assay > Quantification | 1 | 20240722_182545 |
| Pipeline of GD & GBA-PD > Supplement > Seed-Amplification Assay > Quantification > Utility > Sources of aSyn | 1 | 20240722_182549 |
| Pipeline of GD & GBA-PD > Supplement > Sources of aSyn > Skin aSyn > Species > Native conformation > Summary aSyn species | 1 | 20240722_182552 |
| Pipeline of GD & GBA-PD > Supplement > Summary aSyn species > NDE > Fragments (Truncation) > Assay Truncation | 2 | 20240722_182556, 20240722_182559 |
| Pipeline of GD & GBA-PD > Supplement > Summary of a-syn animal models > MOA of aSyn spreading > Antibodies to aSyn > Astrocytic aSyn | 1 | 20240722_182507 |
| Pipeline of GD & GBA-PD > Supplement > Synapse and aSyn > TM for aSyn programs > Turnover of aSyn > ATP13A2 (Park9) | 1 | 20240722_182609 |
| Pipeline of GD & GBA-PD > Supplement > aSyn > Animal models of aSyn > Non-Spreading Models > Spreading Models | 2 | 20240722_182454, 20240722_182501 |
| Pipeline of GD & GBA-PD > Supplement > aSyn > Animal models of aSyn > Spreading Models | 1 | 20240722_182457 |
| Pipeline of GD & GBA-PD > TAK-341 (MEDI1341) > PK/PD model | 1 | 20240722_181818 |
| Pipeline of GD & GBA-PD > Venglustat (Ibiglustat) | 1 | 20240722_181756 |
| Pipeline of Inflammation > CAPS > WBC > Dx > ARP > Sx | 1 | 20240722_183141 |
| Pipeline of Inflammation > Complement / C5aR1 > MOA > Woodruff’s study plan > Screening > DD | 1 | 20240722_183335 |
| Pipeline of Inflammation > NLRP3 inhibitor (Marianthi) > AD > Chemistry > Clinical > Comp Bio > Competitor | 1 | 20240722_183218 |
| Pipeline of Inflammation > NLRP3 inhibitor (Marianthi) > In Vivo strategy > Havrda > HED > IHC | 1 | 20240722_183231 |
| Pipeline of Inflammation > NLRP3 inhibitor (Marianthi) > Katy > Longitudinal > Metabolomics > Microglial Imaging | 1 | 20240722_183244 |
| Pipeline of Inflammation > NLRP3 inhibitor (Marianthi) > Microglial Imaging > NHP > PDE > PE > PET | 1 | 20240722_183255 |
| Pipeline of Inflammation > NLRP3 inhibitor (Marianthi) > PK/PD > PK/PD Strategy > Postmortem > Proteina | 1 | 20240722_183308 |
| Pipeline of Inflammation > NLRP3 inhibitor (Marianthi) > Reactome > Safety > Screening flow > ShareFolder | 1 | 20240722_183321 |
| Pipeline of Inflammation > Pipeline CAPS > Animal model > TM > NLRP3 inhibitor (Marianthi) (PFR-4231-100) | 1 | 20240722_183153 |
| Pipeline of Inflammation > Pipeline CAPS > NLRP3 inhibitor (Marianthi) (PFR-4231-100) > AD > Assays of pyroptosis | 1 | 20240722_183206 |
| Pipeline of Inflammation > Postmortem > Imaging of Iron > IT > Jaya | 1 | 20240722_183348 |
| Pipeline of Inflammation > Pyroptosis MOA | 1 | 20240722_183125 |
| Pipeline of Inflammation > Pyroptosis MOA > Pyroptosis evidence/MOA | 1 | 20240722_183128 |
| Pipeline of Inflammation > Pyroptosis MOA > Pyroptosis evidence/MOA/Correction in PD | 1 | 20240722_183121 |
| Pipeline of LRRK2 > Summary (Schneider…) > DNL201 (=GNE-7…) > Clinical trials | 1 | 20240722_183407 |
| Pipeline of PD | 1 | 20240722_184337 |
| Pipeline of PD > GT | 3 | 20240722_184333, 20240722_184447, 20240722_184516 |
| Pipeline of PD > aSyn - Antibody > aSyn - Small molecules | 1 | 20240722_184327 |
| Pipeline of PD > aSyn - Vaccine | 1 | 20240722_184330 |
| Pipeline of PD > 기타 MOA들 | 1 | 20240722_184351 |
| Pittsburgh University > Burton Lab | 1 | 20240722_184401 |
| Postmortem > Proteina > Reactome > Safety | 1 | 20240722_183314 |
| Preclinical support | 1 | 20240722_184130 |
| Preclinical support > Fibroblasts > PARK2 cells | 1 | 20240722_184103 |
| Prodromal PD > Definition of Prodromal PD > MDS research criteria for prodromal PD | 1 | 20240722_184404 |
| Protein-Protein Interaction (PPI) > Post-Translational Modifications | 1 | 20240722_184656 |
| Proteomics | 1 | 20240722_184653 |
| Proteomics > Issues and Solving | 1 | 20240722_184532 |
| Pyroptosis MOA | 1 | 20240722_183118 |
| Pyroptosis evidence/MOA… | 1 | 20240722_183351 |
| RBD | 1 | 20240722_184434 |
| RBD PDD/DLB > GBA pathway in RBD > NCNP collaboration for RBD > Reference range (normal range) | 1 | 20240722_184437 |
| RBDQ-HO (REM sleep… | 1 | 20240722_184545 |
| RD-DDU > Lysosomal changes in PD > Lysosomal Enzymes > Assessment of lysosome > Marker | 1 | 20240722_183419 |
| Reactome > Safety | 1 | 20240722_183311 |
| Reference range (normal range) | 1 | 20240722_184557 |
| Retina > Issues Retina > Rob Rubens | 1 | 20240722_184440 |
| Rob Rubens | 1 | 20240722_184600 |
| SCOPA-AUT > Shipment > Sigma-1 Receptor (σ1R) > σ1R PET > SILK | 1 | 20240722_184503 |
| SECONDMENT | 1 | 20240722_184453 |
| SILK | 1 | 20240722_184613 |
| SNCA ASO (WAVE) > Clinical plan of SNCA ASO | 1 | 20240722_181835 |
| SNCA BTV (HDO) (PFR-4067-100) > Executive summary (Ryouta Maeda) | 1 | 20240722_181831 |
| Safety > Phospholipidosis | 1 | 20240722_183318 |
| ShareFolder > Mitochondria > Astrocyte > asyn and mitochondria > Evidence in sPD | 1 | 20240722_183436 |
| Sharefolder | 1 | 20240722_184459 |
| Sharefolder > Neurodegeneration | 1 | 20240722_184240 |
| Spatial transcriptomics > Single cell transcriptomics > Gene ontology > [Protein] > Structure of protein > Species of protein > Turnover of proteins > Proteomics | 1 | 20240722_184649 |
| Species difference | 1 | 20240722_184616 |
| Stratification strategy on neuroinflammation > RNA-Seq (Daria) > C5aR1 (Woodruff, Univ of Queensland) | 1 | 20240722_183332 |
| Stratification strategy on… | 1 | 20240722_183521 |
| Stratification strategy on… > Pathogenicity of variant | 1 | 20240722_184310 |
| Structure of mitochondria | 1 | 20240722_183442 |
| Structure of mitochondria > Mitochondrial respiratory chain complexes > Subunits of complex I > MAM (Mitochondria-associated membranes) > Imaging of MAM | 1 | 20240722_183449 |
| Studies of 31P MRS | 1 | 20240722_183508 |
| Studies of 31P MRS > MELAS (Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes) > MJFF | 1 | 20240722_183514 |
| Studies of 31P MRS > Oliver Bandmann, MD,… > MELAS (Mitochondrial enc…) > MJFF | 1 | 20240722_183518 |
| Study population > Type of gene therapy > Units (dose and transgene expression) > [PHARMACOLOGY] | 1 | 20240722_184759 |
| Succinate > Surrogate endpoint > Symptom > Synapse | 1 | 20240722_184513 |
| Summary | 1 | 20240722_183455 |
| Summary > 31P MRS imaging > Principle > Studies of 31P MRS | 1 | 20240722_183511 |
| Symptom > Tx pattern WW | 1 | 20240722_184550 |
| Synapse > Neuronal pentraxins > Synaptic change in PD > Target Identification > TDP43 > TMEM106B > TMEM175 | 1 | 20240722_184519 |
| Synaptic change in PD | 1 | 20240722_184626 |
| TAK-071 > Mechanism | 1 | 20240722_181839 |
| TAK-341 (MEDI1341) > Clinical studies | 1 | 20240722_181822 |
| TAU > TCP > Timeline | 1 | 20240722_183324 |
| TRAP1 > MOA | 1 | 20240722_184535 |
| TRPML1 | 1 | 20240722_184542 |
| Takeda efforts in prodromal PD | 1 | 20240722_184407 |
| Terminology > Psychosis in PD > pipeline > Radiochemical | 1 | 20240722_184420 |
| Timeline > Wipe assay > [Budget] > Definition Budget category | 1 | 20240722_184840 |
| Transfer > Team > Translational questions > RBD+PD | 1 | 20240722_183327 |
| UPS > Metabolomics > Omics > Cis- vs Trans- > Intracellular delivery | 1 | 20240722_184700 |
| USA’s group | 1 | 20240722_183528 |
| Unclassified | 4 | 20240722_184539, 20240722_184629, 20240722_184730, 20240722_184746 |
| Units (dose and transgene…) > [PHARMACOLOGY] > Binding Affinity > PK-PD relationship | 1 | 20240722_184802 |
| Unmet Needs > UPS > MOA of UPS | 1 | 20240722_184553 |
| VMAT Vesicular monoamine transporter-2 > VMAT PET > [18F]AV-133 | 1 | 20240722_184604 |
| Validation > Biomarker milestones > BMx Assay Qualification > Biomarker type-specific definition of milestones | 1 | 20240722_184726 |
| Workflow > Budget/Responsibilities | 1 | 20240722_184833 |
| [BIOMARKER] > Examples of biomarker > Keytruda with MSI-H or dMMR | 1 | 20240722_184740 |
| [BIOMARKER] > Validation > Analytical (=Technical) validation | 2 | 20240722_184733, 20240722_184736 |
| [Budget] > Definition Budget category > Cost center > FY19 | 1 | 20240722_184843 |
| [Budget] > FY21 > FY21 B. KPI-linked proje… | 1 | 20240722_184850 |
| [GT] > AAV > Capsid (serotype) | 1 | 20240722_184743 |
| [Glossary] > Amino Acid Codes | 1 | 20240722_184854 |
| [MOLECULAR BIOLOGY] > Central Dogma Process | 1 | 20240722_184607 |
| [MOLECULAR BIOLOGY] > DNA > cDNA / ASO / DNA structure | 1 | 20240722_184610 |
| [MOLECULAR BIOLOGY] > Mutations > Genotyping Methods | 3 | 20240722_184643, 20240722_184713, 20240722_184756 |
| [MOLECULAR BIOLOGY] > [PET] > Parameters of PET ligand | 2 | 20240722_184809, 20240722_184823 |
| [MOLECULAR BIOLOGY] > [PET] > Regulatory Development Path PET ligand | 1 | 20240722_184836 |
| [PHARMACOLOGY] > Binding Affinity > PK-PD relationship | 1 | 20240722_184806 |
| [PHARMACOLOGY] > Parameters of PET ligand > Dose of PET tracer > PET Steering Committee > Workflow | 1 | 20240722_184819 |
| [PK] > Parameters > Dose-PK-PD-Efficacy relationship > Translational modeling (and prediction of clinical efficacy) using a reference drug (that has clinical data) | 1 | 20240722_184720 |
| [PK] > Parameters > Dose-PK-PD-Efficacy relationship in Vivo | 1 | 20240722_184716 |
| [Protein] > Assays > ELISA > AlphaLISA > PCR > SPR > DNA Synthesis assays > Cell Signaling Assay > Binding affinity assays | 1 | 20240722_184710 |
| [Protein] > Assays > LC-MS vs ELISA > Flow cytometry > FRET > ELISA > Sandwich ELISA > SIMOA > MSD | 1 | 20240722_184706 |
| aSyn programs > aSyn Propagation Suppressor | 1 | 20240722_181827 |
| biomarkers | 1 | 20240722_184506 |
| cGAMP (cyclic GMP-AMP) > Assay development and monthly update | 1 | 20240722_181847 |
| cGAS (cyclic GMP-AMP synthase, cGAMP synthase, =mb21d1) > Senescence | 1 | 20240722_181843 |
| mRNA > miRNA > RNA binding proteins (RBPs) > Transcriptome > Database of transcriptome > Gene Expression Analysis (Transcriptome) > Methods comparison > Interpretation | 1 | 20240722_184646 |
| mitophagy in vivo… > Monthly update > MRI > Classification | 1 | 20240722_184149 |
| polygenic risk score > Steps of PRS STUDY > Results of PRS > eQTL | 1 | 20240722_184636 |
| α-Synuclein and Lewy pathology in Parkinson’s disease > Supplement Positive vs Negative | 1 | 20240722_182120 |
| 기타 MOA들 | 3 | 20240722_184340, 20240722_184348, 20240722_184354 |